Suppression of vascular endothelial cell inflammation Both adaptive and innate immunity tightly regulate atherosclerosis. Vascular endothelial cells (ECs) are targets of proinflammatory cytokines, such as interleukin-1b (IL-1b) and tumor necrosis factor-a (TNF-a). However, the important question of whether ECs play a critical role in initiating vascular inflammation remains poorly defined. In particular, the issue of whether ECs in atherogenic conditions generate excess IL-1b via the newly-defined inflammasome remains unknown. Therefore, the goal of this proposal is to examine a novel hypothesis that EC inflammation with the generation of IL-1b followed by EC apoptosis is accelerated in the pathogenesis of atherosclerosis. The corollary hypothesis is that factors and cells in suppressing EC generation of excess IL- 1b and EC apoptosis play inhibitory roles in atherogenesis. Preliminary data from our lab and reports from others'labs clearly support this hypothesis: (i) Microbial infections play a role in the pathogenesis of atherosclerosis. In response to the stimulation of bacterial lipopolysaccharide (LPS), mouse aortic ECs (MAECs) from atherogenic apolipoprotein E-deficient ApoE-/- mice express higher levels of pro-IL-1b than MAECs from wild-type control mice. The upregulation of pro-IL-1b in MAECs from ApoE-/- mice is increased in the presence of phosphatidylinositol 3-kinase (PI-3K) inhibitors Wortmannin and Ly294002, suggesting that PI3K-Akt survival pathway suppresses IL-1b-generating EC inflammation;(ii) We have identified a novel Bcl-xL interacting, anti-apoptotic protein TCTP. TCTP is an important regulator and anti-apoptotic protein along PI3K- Akt survival pathway. In addition, TCTP is also down-regulated in response to LPS stimulation in ECs, suggesting that anti-TCTP may inhibit EC inflammation and apoptosis as a PI-3K-Akt pathway-signaled protective mechanism of ECs. In addition, we found that co-culture of MAECs from ApoE-/- mice with CD4+CD25highFoxp+ regulatory T cells (Tregs) results in decreased pro-IL-1b expression in response to LPS, suggesting that immunosuppressive Tregs suppress EC inflammation;(iii) IL-1b deficiency inhibits EC inflammation and atherogenesis. Therefore, the elucidation of the suppressive mechanisms of IL-1b-generating EC inflammation and EC apoptosis is clinically significant, as it may lead to new therapeutics for treating atherosclerosis and vascular inflammation. This goal will be pursued through the execution of the following specific aims: (1) To determine whether IL-1b-generating EC inflammation is accelerated in atherogenic ApoE-/- mice in comparison to that in wild-type control mice;(2) To determine whether TCTP and PI3K-Akt intracellular signaling pathway inhibits IL-1b-generating EC inflammation and EC apoptosis in ApoE-/- mice; and (3) To determine whether extracellular suppression of IL-1b-generating EC inflammation and EC apoptosis by Tregs attenuates the atherogenesis in ApoE-/- mice.

Public Health Relevance

There is increasing evidence that vascular endothelial cell (ECs) inflammation significantly contributes to the development of atherosclerosis. However, the important question of whether ECs play a critical role in initiating vascular inflammation remains poorly defined. The proposed studies will provide better understanding whether the elucidation of the suppressive mechanisms of IL-1b-generating EC inflammation and EC apoptosis can lead to the development of new therapeutics for treating atherosclerosis and vascular cell inflammation.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL094451-05
Application #
8452070
Study Section
Special Emphasis Panel (ZRG1-CVS-F (03))
Program Officer
Olive, Michelle
Project Start
2009-07-15
Project End
2014-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
5
Fiscal Year
2013
Total Cost
$353,430
Indirect Cost
$117,810
Name
Temple University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
057123192
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Lopez-Pastrana, Jahaira; Shao, Ying; Chernaya, Valeria et al. (2015) Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells. Transl Res 165:221-40
Meng, Shu; Ciment, Stephen; Jan, Michael et al. (2013) Homocysteine induces inflammatory transcriptional signaling in monocytes. Front Biosci (Landmark Ed) 18:685-95
Huang, Xiao; Gong, Ren; Li, Xinyuan et al. (2013) Identification of novel pretranslational regulatory mechanisms for NF-*B activation. J Biol Chem 288:15628-40
Mai, Jietang; Virtue, Anthony; Shen, Jerry et al. (2013) An evolving new paradigm: endothelial cells--conditional innate immune cells. J Hematol Oncol 6:61
Yin, Ying; Pastrana, Jahaira Lopez; Li, Xinyuan et al. (2013) Inflammasomes: sensors of metabolic stresses for vascular inflammation. Front Biosci (Landmark Ed) 18:638-49
Jin, Ming; Yang, Fan; Yang, Irene et al. (2012) Uric acid, hyperuricemia and vascular diseases. Front Biosci (Landmark Ed) 17:656-69
Mai, Jietang; Virtue, Anthony; Maley, Erin et al. (2012) MicroRNAs and other mechanisms regulate interleukin-17 cytokines and receptors. Front Biosci (Elite Ed) 4:1478-95
Pansuria, Meghana; Xi, Hang; Li, Le et al. (2012) Insulin resistance, metabolic stress, and atherosclerosis. Front Biosci (Schol Ed) 4:916-31
Li, Xinyuan; Mai, Jietang; Virtue, Anthony et al. (2012) IL-35 is a novel responsive anti-inflammatory cytokine--a new system of categorizing anti-inflammatory cytokines. PLoS One 7:e33628
Virtue, Anthony; Mai, Jietang; Yin, Ying et al. (2011) Structural evidence of anti-atherogenic microRNAs. Front Biosci (Landmark Ed) 16:3133-45

Showing the most recent 10 out of 17 publications